Preliminary results from a Phase I trial of a first-generation CAR-T cells targeting the glioblastoma tumor antigen IL13Rα2 reported safe intracranial delivery of the CAR-T cells with one particular patient exhibiting a 79% regression of recurrent tumour mass [106]. Here, IL13RA2 is linked to neoplasm.